topotecan has been researched along with Adenocarcinoma, Papillary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balat, O; Ugur, MG | 1 |
| Chen, TT; Escalon, J; Hills, D; Hochster, H; Ivy, P; Liebes, L; Lu, JM; Muggia, F; Sorich, J | 1 |
1 trial(s) available for topotecan and Adenocarcinoma, Papillary
| Article | Year |
|---|---|
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Topotecan; Treatment Outcome | 2008 |
1 other study(ies) available for topotecan and Adenocarcinoma, Papillary
| Article | Year |
|---|---|
Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature.
Topics: Adenocarcinoma, Papillary; Agranulocytosis; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Quality of Life; Topotecan | 2003 |